Navigation Links
Carilion Clinic Invests in Sight Saving Technology to Improve Patient Care: Carilion Clinic Teams Up with Retasure
Date:8/29/2008

Carilion Clinic teams up with Retasure

Wake Forest, NC (PRWEB) August 29, 2008 -- Digital Healthcare, a Wake Forest, NC company specializing in risk assessment for diabetics, recently announced that the Carilion Clinic of Virginia has selected the Retasure solution to provide retinal imaging risk assessment to diabetic patients.

Carilion Medical Group is one of the largest physician practices in Virginia, and is the largest primary care group in the state. It consists of more than 200 physicians, Nurse Practitioners and Physician Assistants in 70 offices across western Virginia and the Shenandoah Valley. The practice provides care to more than 2,500 diabetics in the region.

"Carilion Medical Group is a very important healthcare provider in this community," says Scott Sanner, Senior Vice President for Digital Healthcare's North American Operations. "They see a large number of patients at risk for vision loss, but it is estimated that up to half of these patients do not have regular eye exams. Being assessed for retinopathy through their PCP will undoubtedly lead to earlier detection -- and prevention -- of vision loss."

The FDA-approved and HEDIS compliant Retasure program provides a simple, affordable, and non-invasive solution that allows physicians to capture their patients' retinal images during a three to five minute procedure. Images are transmitted over a secure, HIPAA compliant network to an accredited reading center. A state-licensed and board-certified ophthalmologist reviews the images and results are returned to the original physician within 72 hours.

There are an estimated 20 million diabetic patients in the US, but only about half have any retinal assessments, despite a high risk of diabetic retinopathy. The National Eye Institute indicates diabetic retinopathy is the leading cause of blindness among working age American adults. More than a million patients around the world have received a retinal risk assessment using Digital Healthcare software.

About Digital Healthcare
Digital Healthcare is the global leader in retinal risk assessment. They are the world's leading provider of care management programs for diabetic retinopathy. Their award-winning MS-HUG technology is used by leading hospitals and research centers including University Hospitals Case Medical Center at Case Western Reserve University, The Wilmer Eye Institute at The Johns Hopkins University and the United States Military. Digital Healthcare's Retasure solution offers several advantages for primary care and endocrinologist physicians and their patients: It can be operated by non-clinicians; it is non-invasive and requires no dilation; it obtains exceptionally high-quality digital images of the retina using a simple-to-operate fundus camera; it returns results quickly to the ordering physicians; and it encourages patient compliance for retinal evaluation and comprehensive eye examinations.

For additional information, please visit www.retasure.com.

# # #

Read the full story at http://www.prweb.com/releases/2008/08/prweb1257154.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):